Medwise Overseas Private Limited

Medwise Overseas Private Limited, established on August 17, 2015, is a private limited company headquartered in Daskroi, Gujarat, India. The company specializes in the manufacturing and export of finished pharmaceutical formulations, including tablets, capsules, syrups, and injections. With an authorized and paid-up capital of ₹5.10 million, Medwise operates as a non-government entity under the Corporate Identification Number (CIN) U21001GJ2015PTC084226.

As of March 2025, Medwise reported a total export value of $4.4 million USD, encompassing 161 shipments across 19 products in 10 therapeutic categories. The company's portfolio is notably concentrated, with the top five products accounting for 55% of total exports. The primary therapeutic categories include Cardiovascular (24.7%), Advanced Antibiotics (16.9%), and Advanced Oncology (16.5%).

Medwise operates multiple manufacturing facilities across India, each specializing in different pharmaceutical formulations. These facilities are equipped with state-of-the-art technologies and infrastructure, collectively spanning over 100,000 square feet. The company emphasizes compliance with international quality standards, ensuring that all products are manufactured at accredited sites in adherence to WHO Good Manufacturing Practices (GMP) norms.

The leadership team at Medwise comprises experienced professionals committed to the company's growth and innovation. Dr. Niral Patel, a Medical Doctor and Pharmacologist from B J Medical College, Ahmedabad, serves as the Promoter Director. His expertise in new product development and creation has been instrumental in the company's success. Dr. Kalpesh Jain, also a Medical Doctor and Pharmacologist from B J Medical College, Ahmedabad, holds the position of Promoter Director. His technical expertise, marketing insight, and visionary thinking have been pivotal in advancing Medwise to the next level.

Medwise has made significant strides in regulated markets, particularly in the United States, European Union, United Kingdom, Australia, and Japan. The company has obtained various certifications, including WHO GMP and ISO 9001:2015, which are essential for market access in these regions. Medwise is actively seeking distribution partners in the USA, indicating a strategic focus on expanding its presence in developed markets.

Medwise has established a presence in emerging markets across Africa, Latin America, and Southeast Asia. The company's adherence to WHO prequalification standards has facilitated access to these regions, enabling it to meet international quality benchmarks and expand its global footprint.

Medwise's geographic strategy demonstrates a balanced approach, with a strong presence in both developed and emerging markets. The company's focus on obtaining international certifications and seeking distribution partners in developed markets like the USA reflects a strategic direction aimed at diversification and reducing concentration risk. This approach positions Medwise to leverage growth opportunities across different regions.

Medwise has made significant progress in the U.S. market, obtaining FDA certifications for its products. The company is actively seeking distribution partners in the USA, indicating a strategic focus on expanding its presence in the U.S. market.

Medwise ensures that all its products are manufactured at accredited sites in compliance with WHO GMP norms. The company has also achieved ISO 9001:2015 certification, reflecting its commitment to quality management systems.

Medwise holds manufacturing licenses from the Central Drugs Standard Control Organisation (CDSCO) and has obtained necessary approvals from state drug controllers. The company has also secured export No Objection Certificates (NOCs), facilitating its international trade operations.

As of March 2026, there are no publicly available records indicating any Form 483 observations, warning letters, or import alerts issued to Medwise by regulatory authorities. This suggests a clean regulatory record, reflecting the company's adherence to compliance standards.

Medwise operates in a competitive landscape with several key players in the pharmaceutical export sector. While specific market share data is not publicly available, Medwise's focus on obtaining international certifications and seeking distribution partners in developed markets like the USA indicates a strategic approach to enhancing its competitive position.

Medwise's key differentiators include its commitment to quality, timely delivery, cost-effectiveness, and post-sale support. The company's unique "Med-Advise" concept offers clients data provision, product suggestions, updated disease guidelines, research articles, weekly updates, and innovative packaging ideas, enhancing customer satisfaction and loyalty.

Medwise's current strategic direction focuses on expanding its presence in both developed and emerging markets. The company's pursuit of international certifications and distribution partnerships reflects a commitment to growth and market diversification. Looking ahead, Medwise aims to strengthen its position in the global pharmaceutical export sector by leveraging its strengths in quality manufacturing and customer-centric services.

Medwise has demonstrated a strong track record in pharmaceutical manufacturing, with a diverse product portfolio and consistent export performance. The company's adherence to international quality standards and its proactive approach to market expansion indicate reliability and a commitment to excellence. Medwise's focus on customer satisfaction and post-sale support further underscores its dedication to building long-term, trustworthy relationships with clients.

Importers should verify the following certifications to ensure product quality and regulatory compliance:

• FDA Certification: Confirm that Medwise's products are FDA-approved for the U.S. market.

• WHO GMP Certification: Ensure that manufacturing facilities comply with WHO Good Manufacturing Practices.

• ISO 9001:2015 Certification: Verify the implementation of quality management systems.

• EU GMP Certification: Check for compliance with European Union Good Manufacturing Practices.

• EDQM Status: Confirm that products meet European Directorate for the Quality of Medicines standards.

These certifications can typically be verified through official regulatory bodies or directly from Medwise's official communications.

Importers should undertake the following steps to ensure a thorough evaluation of Medwise Overseas Private Limited:

• Verify Certifications: Confirm the validity of FDA, WHO GMP, ISO 9001:2015, EU GMP, and EDQM certifications.

• Assess Financial Health: Review the company's financial statements for profitability and stability.

• Evaluate Manufacturing Facilities: Inspect facilities for compliance with international quality standards.

• Check Regulatory Compliance: Ensure adherence to CDSCO and other relevant regulatory requirements.

• Review Export Records: Analyze export volumes and consistency to assess reliability.

• Assess Customer Support: Evaluate the effectiveness of post-sale support and customer service.

Red flags to watch for include expired certifications, unresolved regulatory issues, financial instability, and poor customer feedback. Recommended pre-order checks involve obtaining and verifying all relevant certifications, conducting facility inspections, and reviewing recent customer testimonials.